Hints and tips:
...The initial list of 10 drugs to face price negotiations includes a diabetes pill called Jardiance sold by Boehringer Ingelheim and Eli Lilly; a medicine to prevent strokes called Eliquis made by Pfizer and...
...The ruling was a significant win for the pharmaceutical companies GSK, Pfizer, Sanofi and Boehringer Ingelheim....
...Drugmakers GSK and Boehringer Ingelheim are now rationing inhalers, according to Premier....
...AbbVie reported better than expected earnings and revenue while raising its guidance, as sales of cancer treatments helped the Chicago-based pharmaceutical company which is suffering from the loss of exclusivity...
...Another company, Boehringer Ingelheim of Germany, remains in patent litigation with AbbVie and has no plans for a European launch, despite its medicine being approved for sale in the EU....
...That would have been close to the multiple of 22 times operating earnings before usual deductions used to price Sanofi’s €21.8bn asset swap with Boehringer Ingelheim last year....
...“a mix of companies you recognise — Pfizer, Boehringer, Merck, Amgen and Sandoz — and players that are not so familiar”....
...Addyi was first developed as an antidepressant in the 1990s by Boehringer Ingelheim, the German pharmaceuticals group, but failed to make it through clinical trials....
...At Boehringer, Mr Neumann acknowledges the process is not always smooth....
...Dechra Pharmaceuticals is like one of the rarer breeds of pets it caters to....
...Samsung Biologics ranks third behind Lonza of Switzerland and Boehringer Ingelheim of Germany....
...The group forecast revenue of $2bn-$2.1bn for 2016, a significant jump, part of which stems from the added revenues it will receive from Roxane Laboratories, the business it agreed to buy from Boehringer...
...The former Pfizer and Bayer executive has made dealmaking a key pillar of his strategy to strengthen the pharmaceutical company since taking over last year....
...Shareholders are taking a dim view of the gloomier assessment by Hikma Pharmaceutical of Roxane Laboratories, which it agreed to buy last year....
...Shares in Hikma Pharmaceuticals have taken a dive after it sliced $535m off its offer price for generic medicines business Roxane Laboratories and said it was expecting lower revenues from its acquisition...
...The first was an €18bn asset swap with Boehringer Ingelheim agreed last December, which, once completed, will see Sanofi trade its animal health unit for the German group’s consumer health business....
...Sanofi has long stated its desire to rebuild its position in oncology, which is now the most dynamic area in pharmaceuticals research....
...Another day, another potential pharmaceuticals deal....
...In pharmaceuticals at least, it is making a comeback....
...As head of the firm’s M&A practice, Mr Cooke recently led the team advising Hikma Pharmaceuticals on its $2.65bn acquisition of Roxane from Boehringer Ingelheim, and Shire on its proposed merger with AbbVie...
...Based on 2014 revenues, the combined entity would have ranked 21st among global pharma groups with $12bn of sales, behind Boehringer Ingelheim but above big names such as Biogen....
...Possible buyers include Zoetis and pharma groups that still have animal health divisions: Lilly, Bayer and possibly Boehringer Ingelheim, which is privately held....
...After the rejection Boehringer Ingelheim sold rights in the drug to Sprout Pharmaceuticals, a new company in North Carolina, which has conducted further clinical trials – showing more significant benefits...
...Boehringer Ingelheim of Germany filed for information on InterMune’s products. Both rivals were developing similar compounds....
International Edition